Prognostic value of postoperative and post-ablative serum thyroglobulin levels in patients with differentiated thyroid cancer
Raef, H., Malabu, U.H., Alfadhli, E., Al-Hajjaj, A., Al-Sobhi, S., Rifai, A., and Al-Nuaim, A. (2008) Prognostic value of postoperative and post-ablative serum thyroglobulin levels in patients with differentiated thyroid cancer. Nigerian Journal of Medicine, 17 (4). pp. 391-395.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://www.ajol.info/index.php/njm/artic...
Background: The study was designed to examine the value of post-operative and post-ablative serum thyroglobulin levels and diagnostic whole body scan in predicting remission in patients with differentiated thyroid carcinoma.
Methodology: Serum TG levels and diagnostic iodine-123 whole body scans performed prior to and 6-12 months after 131I ablation for DTC were evaluated in 100 consecutive patients at King Faisal Specialist Hospital Riyadh. Patients were followed up for a period of 7.6 years (range 7-10 years). All patients underwent total thyroidectomy prior to 131I ablation.
Results: Patients with serum TG levels < 8 ng/ml post thyroidectomy (50 patients) also maintained low TG < 8 ng/ml after 131I ablation and had better outcome (60%) remission. On the other hand DTC subjects with higher TG > 8 ng/ml post thyroidectomy (50 patients) 40% remained in remission X2 = 4.00, p = 0.046. For the group with initial high post-operative TG, it became < 8 ng/ml in 34/50 (68%) patients after ablation with 131I and in this subgroup, remission was seen in 16/34 (47%) of patients in contrast to 4/16 (25%) remission rate in those who continue to have TG > 8 ng/ml after ablation. At the end of follow up, 123I-WBS was positive in 4% and 10% of patients with initial TG < 8 ng/ml and TG > 8 ng/ml respectively; X2 = 1.38, p = 0.24.
Conclusion: Post-operative and post-ablative serum TG levels -but not follow up diagnostic WBS- have predictive values and permit selection of patients with higher risk for persistent/recurrent disease.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||differentiated thyroid carcinoma, postthyroidectomy, thyroglobulin, remission|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110306 Endocrinology @ 75%|
11 MEDICAL AND HEALTH SCIENCES > 1112 Oncology and Carcinogenesis > 111209 Solid Tumours @ 25%
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920106 Endocrine Organs and Diseases (excl. Diabetes) @ 100%|
|Deposited On:||09 Nov 2011 11:14|
|Last Modified:||09 Nov 2011 14:42|
Last 12 Months: 0
Repository Staff Only: item control page